Pranav Birje | Senior Correspondent
“This budget represents a pivotal move towards a Vikasit Bharat, emphasizing progress
through targeted support for Garib (poor), Mahilayen (women), Yuva (the youth) and
Annadata (farmers). Key focus areas include employment, skill development, MSME
growth—vital for GDP and exports—and middle-class upliftment.
The full exemption of basic customs duties on three cancer treatment medicines is a
notable advance, promising substantial benefits for both the pharmaceutical sector and
cancer patients. With a ₹2,143 crore allocation under the Production Linked Incentive
(PLI) scheme, India is set to lead globally in pharmaceuticals, with the domestic market
projected to reach USD 130 billion by 2030. These steps are vital for achieving our $5
trillion GDP goal in three years and $7 trillion by 2030.
Moreover, the Prime Minister’s package, Significant funds—₹2 lakh crore for
employment and skill development, and ₹1.48 lakh crore for education—are allocated
to drive job creation. Enhanced focus on women’s workforce participation through
dedicated hostels and targeted skilling programs is also commendable. These initiatives
are expected to deliver a skilled workforce crucial for innovation and precision
industries.
The budget also prioritizes innovation, R&D, and education, fostering advancements
across public and private sectors. The government’s commitment to these areas aims to
boost research, enhance education quality, and develop a competent workforce. This
emphasis will propel India’s technology and manufacturing sectors, positioning the
country as a major global manufacturing hub.”
About Supriya Lifescience Ltd :
Established in the year 1987, Supriya Lifescience Ltd. is a global leading manufacturer of
Active pharmaceutical Ingredients. Our state-of-the-art facility is certified by USFDA,
EDQM, EUGMP, NMPA & Health Canada. The facility is located at Khed, District Ratnagiri
and headquartered in Mumbai, India.
Supriya Lifescience Ltd. has a well-established presence in API Manufacturing with focus
in products of various therapeutic segments like – Anti-Histamine, Anti-Allergics,
Vitamins, Anaesthetics, Anti- Asthmatics etc.
Backed by strong R&D, 14 active USDMFs, 8 active CEPs & Worldwide compliant
facilities (EMA, US FDA, WHO, PMDA, TGA, KFDA, ANVISA). Core business is driven by
Ethical values and EHS standards. The company’s focus is to develop APIs and
Intermediates for both Innovators, Generic companies and we also partner exclusively as CMO.
The company was founded by Dr. Satish Wagh, a first-generation entrepreneur and
technocrat. Armed with technical knowledge, business acumen and an extensive
experience of more than 35 years in the pharmaceutical industry, he has been
instrumental for what Supriya Lifescience is today.